Fungal Microbiome (mycobiome) and Fungi with Probiotic Properties as a Diagnostic Marker, Therapeutic Target and a Tool for Treatment of Intestinal Disorders, Obesity, Metabolic Diseases, Cancer and Neurological Disorders

Tech Id: und000605

Introduction

The gut fungal microbial community “gut mycobiome” interacts with the gut bacterial community and the host immune system to influence disease and health. The inventors identified certain gut fungi that can be novel probiotics ingredients.

 

Technology Description

The invention relates to methods of using fungal mycobiome as a means of treating and/or diagnosing diseases in a subject. The present invention provides a method of diagnosing inflammatory bowel disease based on the composition of fungal strains present in the gut of a subject, and treating the subject by administering a probiotic biotherapy. The present invention provides a method of diagnosing susceptibility to a severe form of ulcerative colitis by detecting the presence of a variant in the gene for Dectin-1 (CLEC7A).

The mammalian gut contains a rich fungal community that interacts with the immune system through the innate immune receptor Dectin-1. Mice lacking Dectin-1 exhibited increased susceptibility to chemically induced colitis, which was the result of altered responses to indigenous fungi. In vivo mouse data: Antifungal therapy ameliorates colitis in Clec7a-/- mice, and CLEC7A associates with UC severity in humans.

 

Advantages/Novelty

• For the first time our inventors show that certain members of the gut mycobiome can also impart useful benefits similar to bacterial probiotics, and can be utilized as probiotics and nutritional ingredients to confer health benefits to the host.

• This invention data suggest that relative changes in the gut mycobiome can be used as prognostic marker of disease management and assessing disease severity

• Modulation of gut mycobiome by using existing therapeutic anti-fungal drugs in some pathologic conditions is suggested to favorably improve the health of the patient.

• This method avoids surgical risks, reduces nutritional impact, and is reversible in the case that side effects are encountered.

 

Applications

This finding can be developed into probiotics ingredients, and a diagnostic test to identify patients with ulcerative colitis.

 

Intellectual Property

US 14/396,468 pending.

 

Publications

Iliev et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012, 336(6086):1314-7. [LINK]

 

Patent Information:
For Information, Contact:
Wenyue Du
Associate - IP Management & Licensing
310-423-2241
wenyue.du@cshs.org
Inventors:
David Underhill
Iliyan Iliev
Keywords:
GI Disorders
Immunology
xMetabolism/ IBD